300 results on '"Kuter, David"'
Search Results
2. How I treat thrombocytopenia in pregnancy
3. Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody
4. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial
5. Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial
6. Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition
7. Biomarkers associated with coronary high-risk plaques
8. New insights into the glycobiology of immune thrombocytopenia
9. Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia
10. Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study
11. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag
12. Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria.
13. SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP
14. Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia
15. How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment
16. Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia
17. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection
18. Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy
19. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting
20. Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study
21. A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia
22. American Society of Hematology 2019 guidelines for immune thrombocytopenia
23. Updated international consensus report on the investigation and management of primary immune thrombocytopenia
24. Markers of autoimmunity in immune thrombocytopenia: prevalence and prognostic significance
25. Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study
26. Cognitive impairment among patients with chronic immune thrombocytopenia.
27. Discovery of a Novel DCAF1 Ligand Using a Drug–Target Interaction Prediction Model: Generalizing Machine Learning to New Drug Targets.
28. Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim
29. Linezolid Does Not Increase the Risk of Thrombocytopenia in Patients with Nosocomial Pneumonia: Comparative Analysis of Linezolid and Vancomycin Use
30. Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians
31. Congenital thrombotic thrombocytopenic purpura (TTP) with placental abruption despite maternal improvement: a case report
32. Avatrombopag for adults with early versus chronic immune thrombocytopenia.
33. Hepatocellular carcinoma in Gaucher disease: an international case series
34. What is the role of novel thrombopoietic agents in the management of acute leukemia?
35. Solution structures of chloroquine–ferriheme complexes modeled using MD simulation and investigated by EXAFS spectroscopy
36. Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double‐blind, placebo‐controlled, global study (FORWARD).
37. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia
38. Multiple spectroscopic and magnetic techniques show that chloroquine induces formation of the μ-oxo dimer of ferriprotoporphyrin IX
39. Donor-derived disorders of hemostasis and thrombosis in liver transplantation: Considerations for deceased donor liver selection.
40. Real-World Experiences with Taliglucerase Alfa Home Infusions for Patients with Gaucher Disease: A Global Cohort Study.
41. Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease.
42. Accumulation of persistent tungsten in bone as in situ generated polytungstate
43. Miglustat therapy in type 1 Gaucher disease: Clinical and safety outcomes in a multicenter retrospective cohort study
44. Structure–activity relationships for ferriprotoporphyrin IX association and β-hematin inhibition by 4-aminoquinolines using experimental and ab initio methods
45. Discovery of a Novel DCAF1 Ligand Using a Drug–Target Interaction Prediction Model: Generalizing Machine Learning to New Drug Targets.
46. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim
47. Platelet Apoptosis and Apoptotic Platelet Clearance by Macrophages in Secondary Dengue Virus Infections
48. Linear free energy relationships predict coordination and π-stacking interactions of small molecules with ferriprotoporphyrin IX
49. What is the potential for thrombopoietic agents in acute leukemia?
50. International consensus report on the investigation and management of primary immune thrombocytopenia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.